Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

IMPORTANCE: The anti–programmed cell death protein 1 (PD-1) antibody pembrolizumab is approved by the US Food and Drug Administration for the treatment of microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors, but the prevalence of MSI-H/dMMR prostate cancer and th...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:JAMA Oncol
Κύριοι συγγραφείς: Abida, Wassim, Cheng, Michael L., Armenia, Joshua, Middha, Sumit, Autio, Karen A., Vargas, Hebert Alberto, Rathkopf, Dana, Morris, Michael J., Danila, Daniel C., Slovin, Susan F., Carbone, Emily, Barnett, Ethan S., Hullings, Melanie, Hechtman, Jaclyn F., Zehir, Ahmet, Shia, Jinru, Jonsson, Philip, Stadler, Zsofia K., Srinivasan, Preethi, Laudone, Vincent P., Reuter, Victor, Wolchok, Jedd D., Socci, Nicholas D., Taylor, Barry S., Berger, Michael F., Kantoff, Philip W., Sawyers, Charles L., Schultz, Nikolaus, Solit, David B., Gopalan, Anuradha, Scher, Howard I.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Medical Association 2018
Θέματα:
Original Investigation
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459218/
https://ncbi.nlm.nih.gov/pubmed/30589920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.5801
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια